Price alert —
Sign in to get a one-time email the moment RVTY crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · RVTY
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.7B | $0.0B | $0.1B | $0.1B | 5.7% | 10.7% |
| 2025-12-31 | $0.8B | $0.1B | $0.1B | $0.2B | 12.7% | 14.5% |
| 2025-09-30 | $0.7B | $0.0B | $0.1B | $0.1B | 6.7% | 11.7% |
| 2025-06-30 | $0.7B | $0.1B | $0.1B | $0.1B | 7.5% | 12.4% |
| 2025-03-31 | $0.7B | $0.0B | $0.1B | $0.1B | 6.4% | 10.9% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare RVTY vs peers
Line RVTY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with RVTY
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| RVTY ★ | $12B | 53.0 | 18.9 | 4.2 | 17.3 | 1.7 | 54.3% | 7.0% | 3.5% | 4.14% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 71.2%
| Holder | Shares | % out |
|---|---|---|
| T. Rowe Price Investment Management, | 22,198,422 | 19.90% |
| Price (T.Rowe) Associates Inc | 10,090,158 | 9.04% |
| Edgepoint Investment Group Inc. | 8,800,863 | 7.89% |
| Janus Henderson Group PLC | 8,348,127 | 7.48% |
| Vanguard Capital Management LLC | 7,329,980 | 6.57% |
| Blackrock Inc. | 7,250,376 | 6.50% |
| Vanguard Portfolio Management LLC | 4,813,167 | 4.31% |
| State Street Corporation | 4,310,313 | 3.86% |
| Victory Capital Management Inc. | 3,372,627 | 3.02% |
| Geode Capital Management, LLC | 2,937,122 | 2.63% |
Insider activity · 90d
15 buys / 0 sells · ratio 15.0 · Finnhub
- McMurry-Heath Michelle BUY 6,513
- McMurry-Heath Michelle BUY 5,248
- Klobuchar Michael A BUY 7,368
- Klobuchar Michael A BUY 6,103
- Witz Pascale BUY 15,985
- Witz Pascale BUY 14,720
- Chapin Samuel R. BUY 22,676
- Chapin Samuel R. BUY 21,411
- Vounatsos Michel BUY 13,977
- Vounatsos Michel BUY 12,712
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-17 | 4 | view · |
| 10-Q | 2026-05-12 | 10-Q | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 4 | 2026-05-11 | 4 | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| 8-K | 2026-05-01 | 8-K | view · |
| 4 | 2026-04-22 | 4 | view · |
| 4 | 2026-03-18 | 4 | view · |
| DEF 14A | 2026-03-16 | DEF 14A | view · |
| 4 | 2026-03-10 | 4 | view · |
| 4 | 2026-02-26 | 4 | view · |
| 4 | 2026-02-25 | 4 | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-19 | 4 | view · |
| 4 | 2026-02-06 | 4 | view · |
| 4 | 2026-02-06 | 4 | view · |
| 4 | 2026-02-06 | 4 | view · |
| 4 | 2026-02-06 | 4 | view · |
| 4 | 2026-02-06 | 4 | view · |
| 4 | 2026-02-04 | 4 | view · |
| 8-K | 2026-02-02 | 8-K | view · |
| 8-K | 2026-01-13 | 8-K | view · |
| 4 | 2025-12-17 | 4 | view · |
| 10-Q | 2025-11-04 | 10-Q | view · |
| 4 | 2025-10-31 | 4 | view · |
| 8-K | 2025-10-27 | 8-K | view · |
| 8-K | 2025-10-24 | 8-K | view · |
| 4 | 2025-09-17 | 4 | view · |
| 4 | 2025-09-17 | 4 | view · |
| 4 | 2025-08-28 | 4 | view · |
| 4 | 2025-08-18 | 4 | view · |
| 4 | 2025-08-18 | 4 | view · |
| 4 | 2025-08-18 | 4 | view · |
| 10-Q | 2025-08-05 | 10-Q | view · |
| 8-K | 2025-07-28 | 8-K | view · |
| 4 | 2025-06-17 | 4 | view · |
| 4 | 2025-05-30 | 4 | view · |
| 10-Q | 2025-05-06 | 10-Q | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 4 | 2025-05-01 | 4 | view · |
| 8-K | 2025-04-28 | 8-K | view · |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolutio…
Options picks · RVTY
ITM + OTM ideas from the latest scanLoading…
Congress trades · RVTY
STOCK Act disclosuresLoading…
SEC filings & insiders · RVTY
EDGAR · liveLoading…
Holders · RVTY
Institutions & insider activityLoading…